A Phase 3 interventional study of BGM0504 and BGM0504 in Type 2 Diabetes (T2DM), sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Active, not recruiting at 4 sites in Indonesia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 16th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 9 in phase 3, and was the 49th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:
Universitas Sriwijaya · Sites in Indonesia
Ages 30–65
Novo Nordisk A/S · Sites in Indonesia, Malaysia, Philippines and 1 more country
Ages 40–70
Indonesia University · Sites in Indonesia
Ages 35–59
Boryung Pharmaceutical Co., Ltd · Sites in Indonesia, Korea, Republic of
Ages 19+
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 10 · Phase 4 8
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 85 across the 52 interventional studies, 1,750 across the 14 observational. Of the 47 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 66 have an industry lead sponsor. The 10 most frequent:
BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
BrightGene Bio-Medical Technology Co., Ltd. has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in Indonesia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07064486Phase 3BrightGene Bio-Medical Technology Co., Ltd.A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia | 2027-04-30 |
| NCT07928661Universitas SriwijayaEffect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | 2026-12 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
○ Have been diagnosed with type 2 diabetes mellitus (T2DM);
Exclusion Criteria:
○ Previous diagnosis of type 1 diabetes, special type diabetes;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Drug: BGM0504
10 mg BGM0504 administered SC once a week.
Drug: BGM0504
1 mg semaglutide administered SC once a week
Drug: Semaglutide
Administered SC
Administered SC
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
Change from baseline in HbA1c after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Change From Baseline in Hemoglobin A1c (HbA1c)
Change from baseline in HbA1c after 12 weeks of treatment.
Time frame: Week 0 to Week 12
Change From Baseline in Body Weight
Change from baseline in body weight after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Percentage of Participants With HbA1c Target Value of <7%
Percentage of Participants With HbA1c Target Value of \<7% after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Percentage of Participants With HbA1c Target Value of <5.7%
Percentage of Participants With HbA1c Target Value of \<5.7%after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Change From Baseline in Fasting Serum Glucose
Change from baseline in FPG after 24 weeks of treatment.
Time frame: Week 0 to Week 24
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 21 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Apr 2027 and completion Jul 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BGM0504
BrightGene Bio-Medical Technology Co., Ltd. →